A novel familial prion disease causing pan-autonomic-sensory neuropathy and cognitive impairment

K. Matsuzono, Y. Ikeda, W. Liu, T. Kurata, S. Deguchi, K. Deguchi and K. Abe

Department of Neurology, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine, Okayama, Japan

Correspondence: Professor Koji Abe, Department of Neurology, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan (tel.: +81-86-235-7365; fax: +81-86-235-7368; e-mail: kmatsuzono51@gmail.com).

Keywords: 2-bp deletion in codon 178, familial case, HSAN, novel gene mutation, pan-autonomic failure, prion disease, sensory neuropathy, stop codon at codon 195

Received: 1 September 2012
Accepted: 30 November 2012

Introduction

Sensory neuropathy is not common in prion diseases, and autonomic failure has not been reported to be the initial or main symptom of prion disease [1]. Here we report a unique familial prion disease with a novel prion gene mutation, pan-autonomic failure, sensory neuropathy and mild cognitive impairment as the initial symptom.

Case report

A 34-year-old Japanese female began to have urinary retention of up to 21 at the age of 26 years. At age 30 years, she developed syncope for 5 min due to orthostatic hypotension. At age 31 years, she suffered from frequent vomiting and diarrhea. Her family tree is shown in Fig. 1a. Her mother developed dementia, urinary disturbance and orthostatic hypotension from frequent syncpe attacks at the age of 47 years. She had thermoanesthesia in her lower limbs. One year after onset, she died without a final diagnosis. The grandfather of the present case is told to have developed dementia with urinary disturbance and orthostatic hypotension at the age of 52 years, and died at the age of 62 years, but no medical record could be obtained.

The present case had a height of 159.5 cm and a body weight of 39.5 kg. Her cognitive function showed mild decline to 27/30 in mini-mental state examination and 21/30 in Montreal cognitive assessment. The muscles in her distal limbs were slightly atrophic, and severe thermoanesthesia and hypoalgesia were present. Her tendon reflexes showed generalized areflexia. Severe orthostatic hypotension was observed from 115/80 mmHg (lying) to 59/35 mmHg (standing).

Cerebrospinal fluid (CSF) analysis showed an elevated protein level of 141 mg/dl, and otherwise normal data. Other laboratory data are shown in Table 1 and Fig 1b–e. Compound muscle action potentials and sensory action potentials were not evoked in bilateral tibial and sural nerves, respectively. Sural nerve biopsy revealed moderate loss of myelinated fibers (Fig. 1f) with no deposits of amyloid material. Unlike normal sural nerve (Fig. 1g), prion protein staining of the biopsy revealed ragged deposits in myelin (Fig. 1h,i). The serum and CSF neuron-specific enolase levels were elevated at concentrations of 35.2 ng/ml and 134.9 ng/ml, respectively. The CSF levels of 14-3-3 and tau proteins were also elevated at 1125 pg/ml and 2994 pg/ml, respectively. Thus, the prion gene was analyzed, revealing a 2-bp deletion (CT) in codon 178 that causes additional variable 25 amino acid at C-terminal from the mutation site to the premature stop codon at codon 195 (Fig. 1j). We examined this mutation by polymerase chain reaction-based restriction fragment length polymorphism analysis using BssSI restriction enzyme [2]. The BssSI restriction site detects mutation of the present 2-bp deletion (Fig. 1k).

There are no brain autopsy data to confirm prion disease in the proband, therefore she was treated as presumed prion disease. Bi-level positive airway pressure was initiated for her in order to avoid sudden death at night, and the patient is living by herself today.

Discussion

We experienced the first case with severe pan-autonomic failure, sensory neuropathy and mild cognitive impairment owing to a novel prion gene mutation. An initial symptom of autonomic failure has not been reported in prion disease. Hereditary sensory and autonomic neuropathies (HSANs) are inherited peripheral neuropathies [3]. HSAN-I is characterized by a slowly progressive loss of pain and temperature sensation with autosomal dominant inheritance. Causative mutations of HSAN-I identified to date occur in five genes [4,5]. On the other hand, other HSAN subtypes are autosomal recessive diseases. Cellular prion protein is expressed in axons and Schwann cells of peripheral nerves; thus, 108 German HSAN patients were surveyed to determine whether a mutation in prion protein was responsible. However, no prion protein mutation was found [6]. Thus, the present case may be classified as a new type of HSAN-I with autosomal dominant inheritance and adulthood onset.

Twenty years disparity in the age of onset and protracted course in the proband are mysterious but difficult to explain because both her mother and grandfather died today. Scrapie-infected transgenic mice expressing prion protein lacking the glycosylphosphatidylinositol membrane anchor, abnormal protease-resistant PrPres was reported deposited as amyloid plaques, rather than the usual non-amyloid form of PrPres, and the mutation of the proband is likely producing anchorless PrP protein [7]. This present case provides important clues to the mechanisms underlying prion disease.

Acknowledgements

We appreciate the cooperation of the patient and her family. This work was partly supported by a Grant-in-Aid for Scientific Research (B) 21390267 from the Ministry of Education, Science, Culture and Sports of Japan, and by Grants-in Aid from the Research Committee of CNS Degenerative Diseases (Nakano I), and grants (Mizusawa H., Nishizawa M., Sasaki H., Sobue G.) from the Ministry of Health, Labour and Welfare of Japan. We thank Dr Tetsuyuki Kitamoto, Department of Neurological Science, Tohoku University School of Medicine, and Dr Katsuya Satoh, Department Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Figure 1 (a) Family tree showing the proband (arrow) and her mother and grandfather suffering from the same disease. (b) DWI MR image showing neither cerebral atrophy nor abnormal signal intensities. (c) $^{99m}$Tc-ECD SPECT showing a decrease in CBF in the right parietal and bilateral occipital lobes in eZIS analysis. (d) Before the sweating test, her body temperature was 36.5 °C. (e) At 35 min after the sweating test, her body temperature became 37.6 °C, but she showed no sweating response. (f) The peripheral nerve biopsy was taken from the left sural nerve. Glutaraldehyde-osmium fixed and Epon-embedded semithin cross-sections were stained with toluidine blue, and were subjected to light microscopic examination. Sural nerve biopsy showing moderate loss of myelinated fibers with toluidine blue staining. (g) Normal sural nerve stained with an antibody for prion protein showing myelin staining. The biopsy specimen was fixed in 10% formalin, and embedded in paraffin. For immunohistochemistry, 4.5-μm sections were incubated in 0.3% H$_2$O$_2$ for 30 min to bleach endogenous peroxidase activity, and then treated by hydrolytic autoclaving to enhance the immunoreactivity of prion protein. Slides were incubated at 4 °C overnight with anti-prion protein antibody (clone 3F4, Millipore, Temecula, CA, USA) diluted at 1:500. Positive staining was visualized by the avidin-biotin-peroxidase complex method with diaminobenzidine as the chromogen. (h) Prion protein staining of the sural nerve biopsy from the proband at low magnification. (i) Prion protein staining of the sural nerve biopsy from the proband showing ragged depositions (arrowheads) in myelin around residual axons at high magnification. (j) Direct polymerase chain reaction (PCR) sequencing of the prion gene of the proband showing the 2-bp CT deletion. The forward sequence is upper and the reverse sequence is lower. It showing mutation site at codon 195. (k) PCR-restriction fragment length polymorphism analysis with the restriction enzyme BssSI, showing only 567-bp PCR products in normal controls 1 and 2, but 567 and 280 bands in the proband with BssSI digestion (upper). The BssSI restriction site detects mutation of the present 2-bp deletion (lower).
1. Nozaki I, Hamaguchi T, Sanjo N, et al. Prospective 10-year surveillance of human prion diseases in Japan. Brain 2010; 133: 3043–3057.
2. Walz R, Castro RM, Velasco TR, et al. Surgical outcome in mesial temporal sclerosis correlates with prion protein gene variant. Neurology 2003; 61: 1204–1210.
3. Verhoeven K, Timmerman V, Mauko B, Pieber TR, De Jonghe P, Auer-Grumbach M. Recent advances in hereditary sensory and autonomic neuropathies. Curr Opin Neurol 2006; 19: 474–480.
4. Rotthier A, Baets J, Timmerman V, Janssens K. Mechanisms of disease in hereditary sensory and autonomic neuropathies. Nat Rev Neuro 2012; 8: 73–85.
5. Davidson GL, Murphy SM, Polke JM, et al. Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort. J Neurol 2012; 259: 1673–1685.
6. Koop O, Timmerman V, De Jonghe P, Ringelstein B, Young P, Kuhlenbaumer G. Absence of mutations in the prion-protein gene in a large cohort of HMSN patients. Neuromuscul Disord 2005; 15: 549–551.
7. Chesebro B, Trililo M, Race R, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 2005; 308: 1435–1439.

Table 1 Comparison of this present case and her mother

|              | Present patient | Her mother |
|--------------|-----------------|------------|
| Onset (year) | 26              | 48         |
| Progress     | Living          | Death at 49|
| MMSE         | 27              | 21         |
| FAB          | 21              | n.e.       |
| OH (mmHg)    | 115/80 (lying)  | 124/88 (lying)|
|              | 59/35 (standing)| 76/54 (standing)|
| Urinary retention | 2000 ml     | 300 ml     |
| Sweating test | General anhidrosis | General anhidrosis |
| CVRR (CV%)   | 1.01            | 0.98       |
| Brain MRI    | No specific finding | Mild atrophy in parietal lobe |
| SPECT        | Decrease of CSF in the right parietal and bilateral occipital lobes | n.e. |
| CSF 14-3-3 protein (μg/mL) | 1125          | (+)       |
| CSF tau protein (pg/mL)      | 2994          | n.e.      |
| Prion gene analysis          | 2-bp deletion | n.e.      |

CSF, cerebrospinal fluid; CVRR, coefficient of variation for R-R interval; FAB, frontal assessment battery; MMSE, mini-mental state examination; MRI, magnetic resonance image; OH, orthostatic hypotension; SPECT, single-photon emission computed tomography.